Cervical Lymphadenopathy of Unknown Primary (Head & Neck Squamous Cell Carcinoma of Unknown Primary, SCCUP)

Definition

A cervical lymph node metastasis (usually squamous cell carcinoma, occasionally adenocarcinoma or melanoma) confirmed histologically, for which no primary tumor is identified despite a thorough clinical, endoscopic, and radiologic workup. It is a dynamic diagnosis - if the primary is later found, it is no longer "unknown" - and accounts for well under 5% of head and neck malignancies (Cummings Otolaryngology Head and Neck Surgery; Scott-Brown's Otorhinolaryngology Head & Neck Surgery, p. 3886).

Why it happens / where the primary usually hides

The oropharynx (tonsil and tongue base) is by far the most common hidden site. Two biological "signatures" now drive the whole workup:

HPV-positive (p16 overexpression on IHC) -> primary almost always in the oropharynx (tonsil/tongue base)
EBV-positive -> primary almost always in the nasopharynx

(Cummings Otolaryngology Head and Neck Surgery, p. 3280; ASCO Guideline on SCCUP)

Clinical evaluation

History and full head/neck exam including flexible nasoendoscopy - smoking/alcohol history, skin exam (cutaneous SCC/melanoma can also present this way), node level and laterality (level V nodes raise suspicion for nasopharynx or scalp/skin primary).
Fine-needle aspiration (FNA) of the node - preferred over open biopsy to avoid disrupting tissue planes before definitive surgery; the FNA sample should be sent for p16 IHC / HPV ISH and EBV (EBER) testing.
Imaging: contrast-enhanced CT (CECT) of the neck is recommended as the initial imaging test (strong recommendation, ASCO Guideline, 2020), followed by PET-CT, which has a primary-site detection yield of roughly 24-37% but a notable false-positive rate in the tonsils (15-39%) (Cummings Otolaryngology Head and Neck Surgery, p. 3282).
Panendoscopy under anesthesia with directed biopsies - historically the mainstay, with only ~25% detection using traditional random biopsies.

The transoral paradigm shift

Newer transoral techniques have dramatically raised detection rates:

Transoral laser microsurgery (TLM) or transoral robotic surgery (TORS) with ipsilateral palatine tonsillectomy plus lingual (tongue base) tonsillectomy/mucosectomy identify the primary in up to 89-94% of cases, compared with ~25% for blind panendoscopy biopsies (Cummings Otolaryngology Head and Neck Surgery, p. 3284-3286).
If p16/HPV IHC is positive and nasopharyngoscopy is negative, the primary is very likely tonsil or tongue base, and bilateral palatine + lingual tonsillectomy is both diagnostic and therapeutic.
Recent systematic reviews (2024) specifically address which patients need oropharyngeal biopsy versus non-oropharyngeal (nasopharyngeal, hypopharyngeal, laryngeal) biopsies, and support risk-stratified biopsy protocols rather than blanket panendoscopy of every mucosal site (PMID: 38773941, 38664927).

Staging

Under the current AJCC/UICC TNM system, unknown-primary cervical nodal disease is classified according to viral status:

EBV-positive -> staged using nasopharyngeal N-categories
HPV/p16-positive -> staged using the p16-positive oropharyngeal N-categories
All other unknown primaries -> the T0 category has been eliminated outside these virus-associated groups, since with no mucosal site identified, the node could theoretically have arisen from any mucosal surface (Scott-Brown's Otorhinolaryngology Head & Neck Surgery, p. 3886; K.J. Lee's Essential Otolaryngology staging tables).

Management

If the primary is found (via transoral surgery, targeted biopsy, or PET-CT), treatment follows the site-specific protocol for that primary.
If no primary is ever identified, treatment is directed by nodal disease and viral/histologic markers:
- HPV-positive disease with a limited nodal burden after transoral resection may allow for treatment de-intensification (reduced-field or reduced-dose radiotherapy), an active area of ongoing trials (PMID: 37844736).
- EBV-positive disease is treated targeting the nasopharyngeal mucosal axis.
- More extensive or bilateral nodal disease with no localized primary is typically managed with comprehensive (bilateral) neck and mucosal-axis radiotherapy +/- chemotherapy, and/or neck dissection, depending on nodal extent and extranodal extension (Washington Manual of Medical Therapeutics).
Surgery alone (neck dissection without adjuvant radiotherapy) may be sufficient in select low-risk patients (single node, no extranodal extension, favorable pathology) - this is the focus of a 2025 systematic review on which SCCUP patients can be offered surgery as sole treatment (PMID: 39800989).

Differential diagnosis to exclude first

Before labeling a neck mass as unknown-primary SCC, benign and other neoplastic causes of cervical lymphadenopathy must be excluded: reactive/infectious lymphadenitis (viral - EBV/CMV, bacterial - group A Streptococcus/S. aureus, mycobacterial, toxoplasmosis, cat-scratch disease), lymphoma, thyroid malignancy, and metastatic melanoma or adenocarcinoma from below the clavicle (Fischer's Mastery of Surgery, p. 1185; Bailey and Love's Short Practice of Surgery, p. 1164).

Prognosis

Historically, patients in whom a primary was eventually identified had better outcomes than true unknown-primary cases, but in the HPV era this gap has narrowed considerably - HPV-positive unknown-primary disease treated with modern transoral and radiation approaches now has a prognosis comparable to known HPV-positive oropharyngeal cancer (Cummings Otolaryngology Head and Neck Surgery, p. 3288).

Note on evidence currency

The core workup principles above align with the 2020 ASCO Guideline on SCCUP and recent (2023-2025) systematic reviews on imaging strategy, biopsy indications, and surgery-alone approaches - I found no evidence contradicting the textbook-based approach, only refinements (e.g., more selective non-oropharyngeal biopsy protocols and expanding criteria for surgery-alone in low-risk disease). If you want, I can pull the specific ASCO recommendation grades or dig into imaging-protocol specifics (CT vs PET-CT sequencing) in more detail.

This is a shared conversation. Sign in to Orris to start your own chat.